3 results
Approved WMOWill not start
The primary objective is to determine the pharmacokinetic characteristics of galantamine after 2 single oral doses in children with Down syndrome. Secondary objectives are to evaluate safety and tolerability.
Approved WMORecruiting
Describe the electrocardiographic changes and areas of late myocardial activation encountered in PLN and PKP2 mutation carriers during ajmaline provocation and the relation of these differences to the development for early stages of arrhythmogenic…
Approved WMOCompleted
to investigate the safety and efficacy of idarucizumab in reversing the anticoagulation effect of dabigatran, in patients who have uncontrolled bleeding or require emergency surgery or invasive procedures.